Skip to main content

Day: March 30, 2023

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022. “Last year (2022) was a year of major transformation, excitement and renewed energy for Lisata, allowing us to enter 2023 with growing momentum as we continue to build an enduring pharmaceutical company,” stated David J. Mazzo, Ph.D., Chief Executive Officer of Lisata. “We believe in the potential of our new development pipeline and take pride in the advancement of our clinical studies in oncology...

Continue reading

Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update

Secured meetings with U.S. and European regulatory agencies Advancing partnership activities in both the U.S. and Europe Ended 2022 fiscal year with cash and cash equivalents of $4.0 million CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2022 fiscal year ended December 31, 2022. Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We made significant advancements throughout 2022. Specifically, we announced topline data from our pivotal ONWARD™ phase 3 clinical trial evaluating the efficacy, safety,...

Continue reading

Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. “2022 was a transformational year for Absci that saw research collaborations with Merck and NVIDIA, and included continued strengthening of our platform, talent, and infrastructure, paving the way for an already-monumental 2023,” said Sean McClain, Founder and CEO. “What the world has been seeing over the last few months with the power of generative AI has been central...

Continue reading

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity investment, and eligibility for future milestone payments and tiered royalties Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided a business...

Continue reading

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., March 30, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2022. Vivos believes that its 2022 and early 2023 accomplishments, including the completion of a capital raise for net proceeds...

Continue reading

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update

– Full enrollment of the LUNA trial anticipated in the second half of 2023 – – LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 – – LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023 –  – Cash runway into 2025 – REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular...

Continue reading

Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate – – Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023 – – Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 – – Cash and cash equivalents, restricted cash, and short-term investments of $219.4M at end 4Q 2022 – SEATTLE, March 30, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial...

Continue reading

HeartCore Reports Fourth Quarter and Full Year 2022 Financial Results

NEW YORK and TOKYO, March 30, 2023 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (“HeartCore” or “the Company”), a leading software development company offering Customer Experience Management Platform (“CXM Platform”) and Digital Transformation (“DX”), reported financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Operational HighlightsGrew total number of global enterprise customers to 903 as of December 31, 2022. Established HeartCore Capital Advisors, Inc., a subsidiary that will execute Go IPO and provide professional consulting services to Japanese companies seeking to list on a major U.S. exchange. Partnered with Works Applications and AIM Consulting to improve their respective digital auditing solutions through its DX suite of offerings. Signed eighth and ninth...

Continue reading

BW Energy: Notification of trade

Notification of trade   With reference to BW Offshore’s stock exchange release dated 30 March 2023, please observe the following.   BW Offshore has entered into a Total Return Swap (“TRS”) agreement with financial exposure to 353 425 shares in BW Energy Limited (“BWE”). The TRS agreement relates to BW Offshore’s Long-Term Incentive Programme (LTIP) adopted in 2019. Expiry date for the TRS agreement is 5 April 2024, and the TRS price is NOK 27.92 per share.   Please see BW Offshore’s stock exchange release for more information.   For further information, please contact: Knut R. Sæthre, CFO BW Energy, +47 91 11 78 76 ir@bwenergy.no   BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased developments. The Company...

Continue reading

Fitch upgrades JDE Peet’s to BBB; Outlook Stable

PRESS RELEASE Amsterdam, 30 March 2023 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company by revenue, today announced that Fitch Ratings has upgraded the company’s credit rating from ‘BBB-‘ to ‘BBB’ with a stable outlook. This upgrade underscores the company’s operating strength, strong financial structure and financial discipline. In its release, Fitch noted: “The upgrade reflects the company’s recent de-leveraging and Fitch’s confidence that management will continue to meet its conservative net debt/EBITDA target of about 2.5x. The rating reflects JDEP’s strong market position in the global coffee industry with strong and broadly stable profitability, supported by the sector’s low price elasticity and the potential for further premiumisation of the company’s products. This combines with low capex requirements...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.